Vincent Rathkolb, MD

Clinical Researcher, in training for Internal Medicine

As part of the „Closing the Loop in Hemodialysis study“ I organized a team that conducted interviews with dialysis patients focusing on volume status in general and interdialytic weight gain (IDWG) versus chronic fluid overload (FO) in particular. The goal is to learn how patients deal with and perceive fluid management, and especially what they may communicate about these two very distinct entities (IDWG versus  FO).

Furthermore, I have been involved in and am currently working on publishing the results of substudy B of the Austrian Coronavirus Adaptive Clinical Trial (ACOVACT). This substudy  randomized patients hospitalized with COVID-19 into withdrawal versus continuation of inhibitors of the Renin Angiotensin System (RAS), and into de novo RAS inhibitor therapy (candesartan) versus (nitrendipine/amlodipine or doxazosin). In the HD & Co Reserach group, we work extensively with a method called „RAS Fingerprinting,“ which utilizes mass spectrometry to quantify the concentration and/or activity of the RAS metabolites. Further information on the RAS fingerprint can be obtained from the Vienna-based company Attoquant.

 

Download CV